Sugi Predict

Sugi Predict / Targets / PPIG

PPIG

Peptidyl-prolyl cis-trans isomerase G · Q13427 · PPIG on Sugi Atlas →

1,940 patent compounds predicted against PPIG, 1,212 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2043239 SCHEMBL2043239 0.83 9/20
SCHEMBL2033696 SCHEMBL2033696 0.72 9/20
SCHEMBL12643636 SCHEMBL12643636 0.60 9/20
SCHEMBL2035499 SCHEMBL2035499 1.00 8/20
SCHEMBL2035501 SCHEMBL2035501 1.00 8/20
SCHEMBL2035819 SCHEMBL2035819 1.00 8/20
SCHEMBL2038175 SCHEMBL2038175 1.00 8/20
SCHEMBL2038219 SCHEMBL2038219 1.00 8/20
SCHEMBL2039389 SCHEMBL2039389 1.00 8/20
SCHEMBL2039673 SCHEMBL2039673 1.00 8/20
SCHEMBL2039766 SCHEMBL2039766 1.00 8/20
SCHEMBL2042114 SCHEMBL2042114 1.00 8/20
SCHEMBL2035376 SCHEMBL2035376 0.94 8/20
SCHEMBL2040168 SCHEMBL2040168 0.79 8/20
SCHEMBL2042889 SCHEMBL2042889 0.77 8/20
SCHEMBL2032655 SCHEMBL2032655 0.75 8/20
SCHEMBL2035436 SCHEMBL2035436 0.72 8/20
SCHEMBL12643696 SCHEMBL12643696 0.65 8/20
SCHEMBL2035755 SCHEMBL2035755 0.64 8/20
SCHEMBL2040412 SCHEMBL2040412 0.60 8/20

Clinical trials — most relevant to PPIG by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) PHASE4UNKNOWN
Alpha Ketoglutarate Enhances Geroprotection In Surgery (AEGIS) PHASE4RECRUITING
Porphozym in the Treatment of Acute Attacks in AIP PHASE2/PHASE3COMPLETED
A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia PHASE3COMPLETED
Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer. PHASE1/PHASE2COMPLETED
Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria PHASE1COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors PHASE1COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors PHASE1COMPLETED
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas PHASE1COMPLETED
Effectiveness of Physiologic Testing in PPI Non-Responders EARLY_PHASE1COMPLETED
Identification of Acute Intermittent Porphyria Modifying Genes nanRECRUITING
Parkinson's Diseases Susceptibility Genes and Pesticides nanCOMPLETED
Studies in Porphyria I: Characterization of Enzyme Defects nanUNKNOWN
Pulmonary Hypertension, Hypoxia and Sickle Cell Disease nanCOMPLETED
Proteomics to Identify Prognostic Markers After CPR and to Estimate Neurological Outcome nanCOMPLETED
Role of Circulating Pyrophosphate as a Biomarker of Mediacalcinosis in Type 2 Diabetic Patients nanRECRUITING
Cerebellar Mutism Syndrome Study nanRECRUITING
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Portable Measurement of Protoporphyrin IX in the Skin nanCOMPLETED
Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing nanCOMPLETED
Insulin and the Polycystic Ovary Syndrome--Weight Reduction Study nanCOMPLETED
Biomarkers in the Diagnosis and Prognosis of NAFLD nanRECRUITING
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders nanCOMPLETED
Expression of Markers Related to Mitochondrial Functionality in Carcinoma of the Urinary Bladder: Comparative Retrospective Analysis Between Recurrent Tumors (Non-responders) and Non-recurrent Tumors (Responders) After Intravesical Treatment With Chemotherapy or Immunotherapy nanUNKNOWN
Clubfoot DNA Repository nanCOMPLETED
Autophagy Bladder Cancer nanUNKNOWN
Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia nanRECRUITING
Longitudinal Study of the Porphyrias nanRECRUITING
Implementation of Molecular Diagnostic Pathways nanUNKNOWN
DNA Single Nucleotide Polymorphisms as Predictors of Toxicity nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PPIG binder may also engage these)

ProteinNameSimilarity
O55035 — 0.999 O55035 →
A2AR02 — 0.998 A2AR02 →
P30415 — 0.992 P30415 →
P30414 — 0.990 P30414 →
Q27450 — 0.990 Q27450 →
Q9LY75 — 0.989 Q9LY75 →
Q3MJK5 — 0.988 Q3MJK5 →
Q3UC65 — 0.987 Q3UC65 →
Q5VTL8 — 0.987 Q5VTL8 →
Q14AX6 — 0.987 Q14AX6 →
Q5T200 — 0.986 Q5T200 →
Q3KPW4 — 0.986 Q3KPW4 →
P97868 — 0.985 P97868 →
Q9CSP9 — 0.985 Q9CSP9 →
Q5XHJ5 — 0.985 Q5XHJ5 →
B0BN49 — 0.985 B0BN49 →
E9Q784 — 0.985 E9Q784 →
Q6H7U2 — 0.985 Q6H7U2 →
Q5BKY9 — 0.985 Q5BKY9 →
Q6AXY7 — 0.984 Q6AXY7 →
YTHDC1 YTH domain-containing protein 1 0.984 landscape →
O14161 — 0.984 O14161 →
E1BB50 — 0.983 E1BB50 →
Q80SY5 — 0.983 Q80SY5 →
Q9QY02 — 0.982 Q9QY02 →
Q5RJP9 — 0.982 Q5RJP9 →
E9Q5K9 — 0.982 E9Q5K9 →
Q498L2 — 0.981 Q498L2 →
TTC14 Tetratricopeptide repeat protein 14 0.981 landscape →
Q9CVI2 — 0.981 Q9CVI2 →